Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-mesothelin CAR-CD40L-expressing T lymphocytes

A preparation of T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the human tumor-associated antigen (TAA) mesothelin (MSLN), and CD40 ligand (CD40L; CD154; TRAP; TNFSF5), with potential immunomodulating and antineoplastic activities. Upon administration, anti-MSLN CAR-CD40L-expressing T lymphocytes specifically target and kill MSLN-expressing tumor cells. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types. CD40L binds to CD40 and activates CD40/CD40L-mediated signaling, which activates monocyte-derived dendritic cells (moDCs), increases the secretion of inflammatory cytokines and further stimulates cytotoxic T lymphocytes (CTLs). This enhances cytotoxicity and anti-tumor immune response.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-MSLN CAR-CD40L-expressing T cells
anti-MSLN CAR-CD40L-expressing T lymphocytes
CD40 ligand expressing MSLN-CAR T cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search